** Biotech firm Beam Therapeutics' BEAM.O shares rise 5.6% to $23.43 premarket
** BEAM said late on Thursday that the U.S. FDA has cleared its marketing application for its experimental drug, BEAM-302, to treat a type of genetic disorder called alpha-1 antitrypsin deficiency (AATD)
** AATD is a rare genetic disorder associated with a considerable burden of lung and liver disease, and for which there are no currently approved curative treatments, co says
** Brokerage BofA Global Research says data from the drug's clinical trial, though early-stage, is "potentially practice-changing"
** Brokerage remains positive on the market for AATD with more than $5 billion unadjusted peak sales
** Thirteen of 17 brokerages rate the stock "buy" or higher, 4 "hold"
** As of last close, BEAM has fallen ~35% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。